Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Enters Deal to Offer $7.6M in Stock

NEW YORK – Diagnostics firm OncoCyte said on Thursday that it has entered into definitive agreements with Pura Vida Investments, a healthcare focused registered investment advisor, and one other unnamed institutional investor, to purchase approximately $7.6 million of the company's common shares in a registered offering. 

In connection with the offering, which is expected to close during the week of January 6, 2020, OncoCyte will sell an aggregate of 3,523,776 common shares at a purchase price of $2.156 per share, the average closing price over the five trading days prior to the execution of the agreement with the two investors.

The firm's CEO Ron Andrews said in a statement that the offering reflects a strategy to strengthen OncoCyte's balance sheet through smaller offerings, allowing it "to remain flexible from a strategic perspective while rapidly progressing commercialization efforts."

The firm expects to bring to market its first test, the assay it recently acquired through its investment in Razor Genomics, during the first quarter of this year. Funds raised in the offering will support that launch, as well as subsequent development and launch efforts for its other test, DetermaVu.

Andrews called the interest from Pura Vida "a testimony" to OncoCyte's strategy and portfolio. "This financing leaves us well positioned to continue the advancement and expansion of our suite of impactful tests for underserved decision points in the lung cancer care continuum," he added.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.